Program – HIV & Hepatitis Nordic Conference 2018 (preliminary)
Open the program in printable format (pdf)
| Wednesday | September 26 |
|---|---|
| Coffe and sandwich will be served from 08.30 | |
| 09.00-10.00 | Registration |
| Opening session Moderators: Magnus Gisslén & Nina Weis |
|
| 10.15-10.20 | Welcome (Nina Weis, Denmark) |
| 10.20-10.50 | Opening Plenary 1 Progress towards reaching the 90-90-90 HIV target in Europe and beyond (Anastasia Pharris, ECDC, Sweden) |
| 10.50-11.00 | Discussion |
| Abstract Session I Moderators: Magnus Gisslén & Nina Weis |
|
| 11.00-11.15 | Oral 1 (10 min + 5 min discussion) HPV genotypes identified in migrant women living with HIV are not covered for by current HPV vaccines; results from an interim analysis Christina Carlander |
| 11.15-11.30 | Oral 2 Frequency of co-expression of inhibitory receptors early in HIV infection determines progression rate in untreated patients. Lydia Scharf |
| 11.30-11.45 | Oral 3 Switching to FTC/TAF from either ABC/3TC or FTC/TDF does not affect central nervous system HIV-1 infection Aylin Yilmaz |
| 11.45-12.00 | Oral 4 Gut mucosal CD4 T cells of immunological non-responders with low CD4/CD8 ratio have increased cytokine production, which may be reduced by probiotics Malin H Meyer-Myklestad |
| 12.00-13.00 | Lunch |
| Plenary Session I Moderators: Matti Ristola & Magnus Gottfredsson |
|
| 13.00-13.30 | Plenary 2 Mortality and morbidity among children and adolescents with perinatal HIV infection (Ruth Goodall, UK) |
| 13.30-13.40 | Discussion |
| 13.40-14.10 | Plenary 3 HIV infected women and breastfeeding (Ellen Moseholm Larsen, Denmark) |
| 14.10-14.20 | Discussion |
| 14.20-14.35 | Short break |
| 14.35-15.50 | BHIVA and HIV Nordic joint session – Aspects on HIV prevention in high-risk-populations Moderators: Magnus Gisslén & Caroline Sabin Speakers: Chemsex (Ann Sullivan, UK) PrEP, implementation in Norway (Frank Olav Pettersen, Norway) Declining HIV prevalence among MSM in London (Ann Sullivan, UK) Discussion |
| 15.50-16.30 | Coffee and exhibition/posters |
| 16.30-17.30 | Satellite Symposium I (Janssen) What you need to know about HIV and bone – a medical education event Moderator: Lars Østergaard, Skejby, Aarhus, Denmark Speakers: Mas Chaponda, Royal Liverpool University Hospital, Liverpool, UK, Steffen Leth, Skejby, Aarhus, Denmark, Jon Wetterberg, Venhälsan, Södersjukhuset i Stockholm |
| 17.30-17.45 | Short break |
| 17.45-18.45 | Satellite Symposium II (GSK/ViiV) Can less be more? Let 2-morrow start 2-day Moderator: Eva Fernvik, Sr Scientific Advisor HIV, GSK/ViiV Healthcare Why use a two drug regimen (2DR)? – Tia Vincent, PhD, Director Global Scientific Affairs, ViiV Healthcare The hiv-patient and stigma – the biggest hurdle for a life with high quality? – Maria Lindberg Reinius, RN, PhD, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet |
| 18.45- | Poster Exhibition with cheese and snacks |
| Thursday | September 27 |
|---|---|
| 08.00-09.00 | Satellite Symposium III – HIV Outcome Stigma inom hälsovårdssystemet – behövs en certifiering? The lecture and concluding panel discussion will take place in Swedish. Speakers: Anders Sönnerborg, Karolinska Institutet, Lars E. Eriksson, Karolinska Institutet, Peter Månehall, HIV-Sverige & a group of panelist for a concluding discussion. |
| 09.00-09.10 | Short break |
| Plenary Session II – Inflammation and reservoirs Moderators: Anders Sönnerborg & Annika Karlsson |
|
| 09.10-09.40 | Plenary 6 Tissue resident T-cells and immunity during acute and chronic HIV-infection (Mike Betts, USA) |
| 09.40-09.50 | Discussion |
| 09.50-10.20 | Plenary 7 Microbial translocation and microbiome dysbiosis in HIV-associated immune activation (Piotr Nowak, Sweden) |
| 10.20-10.30 | Discussion |
| 10.30-11.00 | Coffee and exhibition/posters |
| 11.00-11.30 | Plenary 8 Is it possible to enhance immune function in HIV-infected persons on ART with immune failure? (Michael Lederman, USA) |
| 11.30-11.40 | Discussion |
| Plenary Session III – Living with HIV Moderators: DH Reikvam & Aylin Yilmaz |
|
| 11.40-12.10 | Plenary 9 Life expectancy and long-term outlook in PLHIV (Caroline Sabin, UK) |
| 12.10-12.20 | Discussion |
| 12.20-12.50 | Plenary 10 Recent achievements in Next-Generation Sequencing (NGS) of HIV and possible clinical implications (Roger Paredes, Spain) |
| 12.50-13.00 | Discussion |
| 13.00-14.00 | Lunch |
| Plenary Session IV – Last year’s most important achievements in the HIV research field Moderators: Francesca Chiodi & Jan Gerstoft |
|
| 14.00-14.30 | Plenary 11 Top 5 in basic HIV research 2017-2018 (Jan Albert, Sweden) |
| 14.30-14.40 | Discussion |
| 14.40-15.10 | Plenary 12 Top 5 in clinical HIV research 2017-2018 (Anne-Mette Kjær Lebech, Denmark) |
| 15.10-15.20 | Discussion |
| 15.20-15.40 | Plenary 13 The history of HIV in Finland (Matti Ristola, Finland) |
| 15.40-15.45 | HIV & Hepatitis Nordic Conference 2018 Abstract Award (Matti Ristola, Finland) |
| 15.45-16.15 | Coffee and exhibition/posters |
| 16.15-17.15 | Satellite Symposium IV (Gilead HIV) What is the role of the new integrase inhibitor in the management of HIV patients? Moderator: Leo Flamholc, Department of infectious diseases, Malmö University hospital Lecturer: Joel Gallant, Sr. Director of Medical Affairs, Gilead Scienses Inc, USA |
| Conference dinner |
| Friday | September 28 |
|---|---|
| 08.00-09.00 | Satellite Symposium V (Gilead HCV) Elimination of HCV – experience from Iceland Moderator: Soo Aleman MD, PhD, assoc prof, head of HIV, viral hepatitis and immunodeficiency units at Department of Infectious Diseases, Karolinska University Hospital Lecturer: Valgerður Rúnarsdóttir, Medical Director, Vogur University Hospital Sigurdur Olafsson, Director of Hepatology, Landspitali University Hospital Magnus Gottfredsson, MD, PhD, Landspitali University Hospital |
| Plenary Session V – Last year’s most important achievements in the hepatitis field Moderators: Ola Weiland & Helene Mens |
|
| 09.10-09.40 | Plenary 14 Top 5 in hepatitis research 2017/18 (Martti Färkkilä, Finland) |
| 09.40-09.50 | Discussion |
| Abstract Session II Moderators: Ola Weiland & Helene Mens |
|
| 09.50-10.05 | Oral 5 (10 + 5 min discussion) Acute Hepatitis E Virus Genotype 3 Infection Associated with Acute Pancreatitis Miriam Karlsson |
| 10.05-10.20 | Oral 6 Enhancing the hepatitis C (HCV) care cascade for people who inject drugs (pwid) at the Stockholm needle exchange Martin Kåberg |
| 10.20-11.00 | Coffee and exhibition/posters |
| Plenary Session VI Moderators: Magnus Lindh & Nina Weiss |
|
| 11.00-11.30 | Plenary 15 Update on hepatitis E (Heléne Norder, Sweden) |
| 11.30-11.40 | Discussion |
| 11.40-12.10 | Plenary 16 Can HCC surveillance be stopped?/ Post SVR surveillance (Sofie Hallager, Denmark) |
| 12.10-12.20 | Discussion |
| 12.20-13.20 | Lunch |
| Plenary Session VII Moderators: Leo Flamholc & Ola Weiland |
|
| 13.20-13.50 | Plenary 17 HCV treatment in needle exchange programs (Marianne Alanko, Sweden) |
| 13.50-14.00 | Discussion |
| 14.00-14.30 | Plenary 18 HCV treatment in the prison systems (Soo Aleman, Sweden) |
| 14.30-14.40 | Discussion |
| 14.40-15.10 | Plenary 19 Global Perspectives on HCV Eradication (Jeff Lazarus, UK) |
| 15.10-15.20 | Discussion |
| 15.20-15.30 | Concluding remarks Moderator: Magnus Gisslén |